You are invited to our upcoming webinar  

.

Cell Testing for Adventitious Viruses: A Game Changing Approach using High-Throughput Sequencing

The use of high-throughput sequencing (HTS) to identify viral contamination of biological products is extremely sensitive and provides a broad range of detection. PathoQuest has developed a new approach to differentiate inert versus active viral sequences to assist customers with de-risking the production process. This new method enables the ability to identify newly synthesized RNAs, an unequivocal sign of the presence of a transcriptionally active virus. This game changing methodology can be used by biopharmaceutical companies to improve the sensitivity and specificity of testing for adventitious viruses and to reduce the overall time needed for viral testing, thus reducing the time required to achieve a marketable product. This new testing approach, which can be validated in line with GLP and GMP requirements, is applicable to cell banks, cell therapy drug products, vaccines, and raw materials and also has industrial application for virus inactivation testing and testing for the lack of replication-competent viruses in vector stocks.

Join us to learn how this new testing approach can help related to the identification of adventitious viruses in biologics.

Date: Tuesday, September 10, 2019

Time: 5:00 p.m. Central European Summer Time (Paris)
           11:00 a.m. Eastern Daylight Time (Boston)
           8:00 a.m. Pacific Daylight Time (San Francisco)

Duration: 30 minutes plus 15 minutes Q&A

You can pre-register for this free webinar by clicking on the “REGISTER” button above. After registering, you will receive a confirmation email with more details.

About the Presenter:

Marc Eloit, DVM, PhD
Pathogen Discovery Laboratory
Institut Pasteur & PathoQuest Founder
Paris, France

Marc Eloit is Professor of Virology at the Veterinary School of Maisons-Alfort and the head of the Pathogen Discovery laboratory at Institut Pasteur Paris, which is using Next Generation Sequencing as a routine method for discovering new viruses in human patients and animal reservoirs. He has been a member of the Virus Safety Committee, French Agency of Medicinal Products (1992-2012). He has served as a consultant to many companies on the field of virus safety of biologicals. He founded in 2010 Pathoquest, a spin-out of Institut Pasteur dedicated to the identification of pathogens using untargeted Next Generation Sequencing. He has been its CSO till the end of 2016 and acts currently as a scientific advisor for the company.

Sponsored by: